$SNY

Nine European pharmaceutical giants, including Sanofi and AstraZeneca, urge Europe to boost competitiveness. They cite $600B in U.S. and China investments, warning of losing ground to global rivals. The companies highlight the sector's historical success and call for government action.

Florida Attorney General James Uthmeier filed a lawsuit against Eli Lilly, Novo Nordisk, Sanofi, and three PBMs, accusing them of price-fixing and anti-competitive behavior in insulin and diabetes-related drugs. The lawsuit seeks damages and injunctions under Florida's trade and antitrust laws.

Florida sued Eli Lilly, Sanofi, Novo Nordisk, CVS, and others in an antitrust case. The state alleges collusion to inflate insulin and weight-loss drug prices. The lawsuit claims rebates were exchanged for preferred formulary placement.

European drugmakers, including AstraZeneca, GSK, and Novartis, called for increased government spending, faster trials, and stronger IP protections to compete with the US and China. They warned of a decline in Europe's pharmaceutical industry, citing a drop in R&D share and clinical trials. Europe spends 1% of GDP on pharmaceuticals, compared to 2% in the US and 1.8% in China. Industry experts highlight slower European policies as a concern for investment decisions.

Sanofi (SNY) outlined an R&D reset at the Bank of America Global Healthcare Conference, focusing on disciplined pipeline review and external innovation. Shares trade near a 52-week low at $42.50, down 9% YTD, despite being deemed undervalued. The company terminated several programs and aims for a 50/50 split between internal and external innovation. Management expects proof points in 2026-2028, with a solid financial foundation and strategic focus on immunology, vaccines, and rare diseases.

Sanofi and Cheplapharm will partner, with Cheplapharm taking over 20 mature medicines and three sites, while Sanofi gains a 26.4% stake. The deal, set to complete by Q3 2027, aims to optimize operations and maintain supply continuity. Both companies highlight strategic growth and innovation focus.

Sanofi aims for €25B in Dupixent sales by 2030, driven by growth in existing and new markets. The company is exploring M&A opportunities, including larger deals or multiple smaller transactions, to bolster its portfolio. Dupixent grew over 30% in H1 2023, with €5B in Q2 sales. Sanofi also continues discussions with Regeneron on potential follow-on assets for their alliance.

Regeneron (REGN) and Sanofi (SNYNF) completed a long-term safety extension trial for itepekimab in COPD patients. The double-blind study evaluated the drug's safety and tolerability over 72 weeks. The trial's completion and positive results could reduce perceived risks, support a COPD launch, and enhance the companies' revenue outlook in respiratory care.

Sanofi (SNY) has initiated a Phase 1/2 trial for an mRNA vaccine targeting moderate to severe acne in teens. The trial aims to assess safety and efficacy of the vaccine, which is administered in three doses. The study is not yet recruiting, with protocol refinements ongoing. Success could expand Sanofi's mRNA portfolio beyond infectious diseases, potentially benefiting investor sentiment.

Novo Nordisk rebranded to 'Novo' and announced AI collaborations with Anthropic and a $1.4B partnership with Orbis Medicines. Bayer's KERENDIA received FDA approval for Type 1 diabetes CKD. GSK and Sanofi made strategic moves in acquisitions and portfolio simplification.